Report on regulatory flexibilities implemented by national regulatory authorities during the pandemic
ICMRA and the World Health Organization (WHO) have reviewed some of the practices applied by regulatory authorities worldwide to respond to the challenges faced during the COVID-19 pandemic. Their report features concrete examples of regulatory flexibilities and extraordinary measures put in place in different areas of medicines regulation, including, among others, clinical trial oversight, marketing authorisation, inspections and pharmacovigilance.